Radius Health Inc. set a price of $19,500 per year for its newly approved osteoporosis drug Tymlos (abaloparatide), which the company believes will improve access to the daily injectable medicine for cost-sensitive patients – and which may help it gain market share from an established product.
Radius CEO Bob Ward is confident that Tymlos, which won US FDA approval on April 28, can achieve blockbuster status. However, with a mechanism that's similar to Eli Lilly & Co.'s 15-year-old drug Forteo (teriparatide), the company may need to do more than set a wholesale acquisition cost (WAC) that's substantially below the competing product to generate $1bn or more in annual sales